News & Events
Insight Genetics, Inc. today announced the launch of its Insight RET Screen™, a Clinical Laboratory Improvement Amendments (CLIA)-validated assay available through Insight Molecular Labs, that detects oncogenic RET (Rearranged during Transfection) expression in non-small cell lung cancer (NSCLC) patients.
Insight Genetics was featured as local leader in personalized medicine in the July 2015 issue of Nashville Medical News.
Dr. Rachel Skelton, Insight Genetics’ Regulatory Scientist I, presented at the 4th Annual Clinical Operations in Oncology Trials East Coast 2015 conference on July 15, 2015 in Boston, Massachusetts.
Dr. Stephan Morris, Insight Genetics’ Scientific Founder and Chief Scientific Officer, presented at the San Francisco State University Biology Conference, “Personalized Medicine 8.0: Genetic Screening Symposium & Predictive Medicine” on May 28, 2015.
QIAGEN hosted a webinar with presentations by Insight Genetics Chief Scientific Officer Dr. Stephan Morris and Dr. David Saltman, medical oncologist at the British Columbia Cancer Agency, on developments and challenges in anaplastic lymphoma kinase (ALK) testing for the advancement of precision medicine for non-small cell lung cancer (NSCLC) patients.